de Visser AW - Search Results

1

Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.

Norrby M, Vesikari T, Lindqvist L, Maeurer M, Ahmed R, Mahdavifar S, Bennett S, McClain JB, Shepherd BM, Li D, Hokey DA, Kromann I, Hoff ST, Andersen P, de Visser AW, Joosten SA, Ottenhoff THM, Andersson J, Brighenti S. Norrby M, et al. Among authors: de visser aw. Vaccine. 2017 Mar 14;35(12):1652-1661. doi: 10.1016/j.vaccine.2017.01.055. Epub 2017 Feb 17. Vaccine. 2017. PMID: 28216183 Free article. Clinical Trial.

2

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.

van Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA, O'Dee DM, Graves A, Thierry-Carstensen B, Andreasen LV, Ruhwald M, de Visser AW, Agger EM, Ottenhoff TH, Kromann I, Andersen P. van Dissel JT, et al. Among authors: de visser aw. Vaccine. 2014 Dec 12;32(52):7098-107. doi: 10.1016/j.vaccine.2014.10.036. Epub 2014 Oct 30. Vaccine. 2014. PMID: 25454872 Free article. Clinical Trial.

3

Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study.

Roukens AH, Soonawala D, Joosten SA, de Visser AW, Jiang X, Dirksen K, de Gruijter M, van Dissel JT, Bredenbeek PJ, Visser LG. Roukens AH, et al. Among authors: de visser aw, de gruijter m, visser lg. PLoS One. 2011;6(12):e27753. doi: 10.1371/journal.pone.0027753. Epub 2011 Dec 7. PLoS One. 2011. PMID: 22163273 Free PMC article. Clinical Trial.

4

Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals.

Burkhard J, Ciurea A, Gabay C, Hasler P, Müller R, Niedrig M, Fehr J, Villiger P, Visser LG, de Visser AW, Walker UA, Hatz C, Bühler S. Burkhard J, et al. Among authors: de visser aw. Vaccine. 2020 Apr 23;38(19):3610-3617. doi: 10.1016/j.vaccine.2019.12.042. Epub 2020 Jan 5. Vaccine. 2020. PMID: 31911033

5

Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication.

Wieten RW, Jonker EF, Pieren DK, Hodiamont CJ, van Thiel PP, van Gorp EC, de Visser AW, Grobusch MP, Visser LG, Goorhuis A. Wieten RW, et al. Among authors: de visser aw. Vaccine. 2016 Mar 4;34(10):1247-51. doi: 10.1016/j.vaccine.2016.01.037. Epub 2016 Feb 1. Vaccine. 2016. PMID: 26845742

6

Association of polymorphisms in IL-12/IFN-gamma pathway genes with susceptibility to pulmonary tuberculosis in Indonesia.

Sahiratmadja E, Baak-Pablo R, de Visser AW, Alisjahbana B, Adnan I, van Crevel R, Marzuki S, van Dissel JT, Ottenhoff TH, van de Vosse E. Sahiratmadja E, et al. Among authors: de visser aw. Tuberculosis (Edinb). 2007 Jul;87(4):303-11. doi: 10.1016/j.tube.2007.02.001. Epub 2007 Mar 27. Tuberculosis (Edinb). 2007. PMID: 17392024

7

17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.

Wieten RW, Goorhuis A, Jonker EFF, de Bree GJ, de Visser AW, van Genderen PJJ, Remmerswaal EBM, Ten Berge IJM, Visser LG, Grobusch MP, van Leeuwen EMM. Wieten RW, et al. Among authors: de visser aw. J Infect. 2016 Jun;72(6):713-722. doi: 10.1016/j.jinf.2016.02.017. Epub 2016 Mar 24. J Infect. 2016. PMID: 27017899

8

Iron deficiency and NRAMP1 polymorphisms (INT4, D543N and 3'UTR) do not contribute to severity of anaemia in tuberculosis in the Indonesian population.

Sahiratmadja E, Wieringa FT, van Crevel R, de Visser AW, Adnan I, Alisjahbana B, Slagboom E, Marzuki S, Ottenhoff TH, van de Vosse E, Marx JJ. Sahiratmadja E, et al. Among authors: de visser aw. Br J Nutr. 2007 Oct;98(4):684-90. doi: 10.1017/S0007114507742691. Epub 2007 Apr 30. Br J Nutr. 2007. PMID: 17466092

9

Long-term immunity after a single yellow fever vaccination in travelers vaccinated at 60 years or older: A 10-year follow-up study.

Rosenstein MD, de Visser AW, Visser LG, Roukens AHE. Rosenstein MD, et al. Among authors: de visser aw. J Travel Med. 2021 Dec 29;28(8):taab126. doi: 10.1093/jtm/taab126. J Travel Med. 2021. PMID: 34401911 Free PMC article.

10

Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial.

Roukens AHE, van Halem K, de Visser AW, Visser LG. Roukens AHE, et al. Among authors: de visser aw. Ann Intern Med. 2018 Dec 4;169(11):761-765. doi: 10.7326/M18-1529. Epub 2018 Nov 27. Ann Intern Med. 2018. PMID: 30476963 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters